MedTrace Logo

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

NCT03923257 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2021-06-08

No results posted yet for this study

Summary

This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DOTA-OCTREOTATE in children and adolescents with neuroendocrine tumors and pheochromocytoma or paraganglioma.

Conditions

Interventions

DRUG

177Lu-DOTA-tyr3-OCTREOTATE

This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.

PROCEDURE

Peptide Receptor Radiotherapy (PRRT)

PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.

Sponsors & Collaborators

  • Advanced Accelerator Applications

    collaborator INDUSTRY

  • Sue O'Dorisio

    lead OTHER

Principal Investigators

  • M. Sue O'Dorisio, MD, PhD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2021-06-03
Completion
2021-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923257 on ClinicalTrials.gov